<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37072891</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-453X</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>American journal of clinical oncology</Title><ISOAbbreviation>Am J Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Long COVID in Cancer: A Matched Cohort Study of 1-year Mortality and Long COVID Prevalence Among Patients With Cancer Who Survived an Initial Severe SARS-CoV-2 Infection.</ArticleTitle><Pagination><StartPage>300</StartPage><EndPage>305</EndPage><MedlinePgn>300-305</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/COC.0000000000001005</ELocationID><Abstract><AbstractText Label="OBJECTIVES">The long-term effects of severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019 [COVID-19]) infection in patients with cancer are unknown. We examined 1-year mortality and prevalence of long COVID in patients with and without cancer after initial hospitalization for acute COVID-19 infection.</AbstractText><AbstractText Label="METHODS">We previously studied 585 patients hospitalized from March to May 2020 with acute COVID-19 infection at Weill Cornell Medicine (117 patients with cancer and 468 age, sex, and comorbidity-matched non-cancer controls). Of the 456 patients who were discharged, we followed 359 patients (75 cancer and 284 non-cancer controls) for COVID-related symptoms and death, at 3, 6, and 12 months after initial symptom onset. Pearson &#x3c7; 2 and Fisher exact tests were used to determine associations between cancer, postdischarge mortality, and long COVID symptoms. Multivariable Cox proportional hazards models adjusting for potential confounders were used to quantify the risk of death between patients with and without cancer.</AbstractText><AbstractText Label="RESULTS">The cancer cohort had higher mortality after hospitalization (23% vs 5%, P &lt; 0.001), a hazard ratio of 4.7 (95% CI: 2.34-9.46) for all-cause mortality, after adjusting for smoking and oxygen requirement. Long COVID symptoms were observed in 33% of patients regardless of cancer status. Constitutional, respiratory, and cardiac complaints were the most prevalent symptoms in the first 6 months, whereas respiratory and neurological complaints (eg, "brain fog" and memory deficits) were most prevalent at 12 months.</AbstractText><AbstractText Label="CONCLUSIONS">Patients with cancer have higher mortality after hospitalization for acute severe acute respiratory syndrome coronavirus 2 infections. The risk of death was highest in the first 3 months after discharge. About one-third of all patients experienced long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fankuchen</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rajan</LastName><ForeName>Mangala</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Swed</LastName><ForeName>Brandon</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hidalgo</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yamshon</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pinheiro</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Manish A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-6913-9655</Identifier></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR000457</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002384</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Clin Oncol</MedlineTA><NlmUniqueID>8207754</NlmUniqueID><ISSNLinking>0277-3732</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000359" MajorTopicYN="N">Aftercare</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>0</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37072891</ArticleId><ArticleId IdType="mid">NIHMS1904924</ArticleId><ArticleId IdType="pmc">PMC10280943</ArticleId><ArticleId IdType="doi">10.1097/COC.0000000000001005</ArticleId><ArticleId IdType="pii">00000421-202307000-00004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>America Cancer Society. Cancer treatment and survivorship facts and figures, 2022-2024. Atlanta: American Cancer Society; 2022.</Citation></Reference><Reference><Citation>Fillmore NR, La J, Szalat RE, et al. . Prevalence and outcome of COVID-19 infection in cancer patients: a National Veterans Affairs Study. J Natl Canc Inst. 2021;113:691&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665587</ArticleId><ArticleId IdType="pubmed">33031532</ArticleId></ArticleIdList></Reference><Reference><Citation>Brar G, Pinheiro L, Shusterman M, et al. . COVID-19 severity and outcomes in patients with cancer: a matched cohort study. J Clin Oncol. 2020;38:3914&#x2013;3924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7676890</ArticleId><ArticleId IdType="pubmed">32986528</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LY, Cazier JB, Angelis V, et al. . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919&#x2013;1926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255715</ArticleId><ArticleId IdType="pubmed">32473682</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43:435&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">26377897</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23(suppl 8):viii6&#x2013;viii9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4085883</ArticleId><ArticleId IdType="pubmed">22918931</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, et al. . The immunology and immunopathology of COVID-19. Science. 2022;375:1122&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. World Health Organization; 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27:28&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, et al. . Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Devine O, Reese HE, et al. . Point prevalence estimates of activity-limiting long-term symptoms among US Adults &gt;=1 month after reported SARS-CoV-2 Infection, November 1, 2021. J Infect Dis. 2023;227:855&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9278232</ArticleId><ArticleId IdType="pubmed">35776165</ArticleId></ArticleIdList></Reference><Reference><Citation>Martimbianco ALC, Pacheco RL, Bagattini AM, et al. . Frequency, signs and symptoms, and criteria adopted for long COVID-19: a systematic review. Int J Clin Pract. 2021;75:e14357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8236920</ArticleId><ArticleId IdType="pubmed">33977626</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, et al. . Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13:3528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingery JR, Safford MM, Martin P, et al. . Health status, persistent symptoms, and effort intolerance one year after acute COVID-19 infection. J Gen Intern Med. 2022;37:1218&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786200</ArticleId><ArticleId IdType="pubmed">35075531</ArticleId></ArticleIdList></Reference><Reference><Citation>
Team RCR. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. https://www.r-project.org/
</Citation></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai C, Feng X, Lu M, et al. . One-year mortality and consequences of COVID-19 in cancer patients: a cohort study. IUBMB Life. 2021;73:1244&#x2013;1256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426703</ArticleId><ArticleId IdType="pubmed">34318585</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4:e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med. 2021;24:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. . Immunological dysfunction persists for 8 montsh following intial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23:194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">11239407</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao J, Liu Z, Fu YX. Adapting conventional cancer treatment for immunotherapy. J Mol Med (Berl). 2016;94:489&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">26910191</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2021;72:340&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337668</ArticleId><ArticleId IdType="pubmed">33501974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>